The development of exosome monitoring marker in pancreatic cancer

Phase 1

Recruiting

• Conditions: pancreatic cancer, pancreatic benign disease (chronic pancreatitis, IPMN); pancreatic cancer, exosome; D010190, D050500, D000077779

• Registration Number: JPRN-jRCT1030230227
• Lead Sponsor: ana Shimamoto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-14
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

(1) Individuals who was diagnosed with pancreatic cancer and untreated.
(2) Individuals who attend the hospital under the diagnosis of the benign pancreatic disease.
(3)Individuals who did not have a pancreatic cancer or the benign pancreatic tumor and visit Jikei medical chekup center.
(4) Individuals aged 20 and over.

Exclusion Criteria

(1) Individuals who declined to participate in the research.
(2) Individuals who are pregnant.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference in the amount of exosomes at the baseline among the pancreatic cancer, benign pancreatic disease and healthy control.

Secondary Outcome Measures

Name	Time	Method
1) Difference in the change in exosome levels before and after chemotherapy between the chemotherapy responsive and non-responsive groups.<br>2) Quantitative evaluation of the difference in exosome protein immunohistochemical staining (IHC) of FNA and surgical specimens between the chemotherapy responsive and non-responsive groups.<br>3) Difference in the exosome level compared at the baseline and at the reccurence.